Version 1.0.3

Submission
Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/07/2016
Deadline Date	29/07/2016
Date Submitted	28/07/2016
Туре	Historic Performance in Initiating
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 25 of 32. Pages: 1 2 Next >

	∞ 1	8	<u>&</u>	- d
-	1972 1	1971 1	4931	
	84972 10/H1313/2 21860	84971 14/EM/0172 142310	84931 13/NW/0501 123836	Research Ethics Committee Reference Number
	21860	142310	123836	Integrated Research Application System Number
	NHS Permission	NHS Permission	HRA Approval	Submission Type
DARATUMUMAB: An Open-Label Treatment Use	LuCID: Longitudinal European Clostridium difficile Injection Diagnosis	BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term bables.	QUAZAR CC-486- AML-001: A Phase 3, ramdomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care supportive care supportive care supportive care therapy in subjects with acute myeloid Leukemia in	Name of Trial
	27/08/2015	13/10/2015		Date of Receipt of Valid Research Application
	11/09/2015	12/02/2016		Date of First NHS Patient Permission Recruited?
	No	No	8	
				Date of First Patient Recruited
	15	122		Duration between VRA and NHS Permission
		,	*	Duration Dura between betw NHS VRA Permission and and First First Patient Patia
			4	ation reen ant
			114	Duration Detween between Date Site Site Confirmed R
				Duration Duration Date Site Confirmed Sand First Patient Recruited F
	N _O	N _o	Z _o	Duration between Date Site Selected W and First Patient Recruited
	ō	ō		Benchmark Date Site Met Invited
			12/01/2016	
			12/01/2016	Date Site A
			12/01/2016 12/01/2016 25/04/2016 26/04/2016 05/05/2016 Sel	HRA Approval E Date S
			:5/04/2016	Date Site Confirmed Date Site By Confirme Sponsor
	6-)5/05/2016	Ω.
	Sel-	S Ple	e o	No. Co. Sta

85086	85085	84975	84974	84973 1	
85085 13/EM/0348 -		84975 14/YH/1056	84974 15/LO/1807	84973 15/WM/0457 195511	
183975	122371	147421	187302		
NHS Permission	NHS Permission	HRA Approval	NHS Permission	NHS	
PEARLS: A randomised, phase 3 trial with anti-PD-2 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of	Monoprost compared with Lumigan in POA glaucoma/ocular hypertention	AB 10004 Study- A Multicenter, Randomised, Open-label, three- parallel groups, phase 2-3 study to evuate the effiency and safety of masitinib with dexamenthasone, gemcitabine with dexamethasone and the combination of mastinib, gemcitabine and dexamethasone	Checkmate 331 An Operr-label, Randomized, Phase 3 study of Nivolumab or chemotherapy in subjects with replases small-cell lung cancer after Platinum- Based first line chemotherapy. CA209-331	Protocol for Daratumumab in Subjects with Mulitple Muyeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteas	
21/03/2016	26/10/2015		25/01/2016	02/03/2016	
21/04/2016	30/10/2015		23/02/2016	10/03/2016	
Z 0	No	Z	Yes	Yes	
			20/07/2016	22/03/2016	
31	4		29	œ	
			148	12	
			177	20	
		8			
	Z ₀	Z	Z _o	Yes	
•	0				
		01/03/2016 21/03/2016			
		22/06/2016 23			
		23/06/2016 24	4 .		
פר ט	συ	24/06/2016 Ple Sel	P le	Ple Set	
S P e e	S _e .	I <u>o</u> <u>o</u>	<u> </u>	I ÷ ø	

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=39&SubmissionId=4222&TrustId=1119

ŧ –			T		
, -	35090	35089	85088	85087	
,	85090 14/WM/1055 152229	85089 14/SS/1043	85088 15/EE/0326	85087 13/LO/1463	
ibasiasi		142447	185205	130983	
	NHS Permission	NHS Permission	NHS Permission	NHS Permission	
MORAb-009-201 A		UNIRAD: Randomized, doubled-blind, multicentre phase 111 trail evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2 - primary breast cancer who remain free of disease after receiving	Seattle Genetics: SGN35-023 A randomised, open label, phase 2 study of rituximab and bendamustine with or without brentuximab vedotin for relapsed or refractory CD30- positive diffuse large B-cell lymphoma	InterAACT - A Multicentre Randomised Phase 11 Advanced Anal Cancer Trial	standard adjuvant therapy
	10/07/2015	06/03/2016	23/03/2016	09/06/2015	
	23/07/2015	09/03/2016	04/04/2016	16/07/2015	
	Yes	No	No	Z o	
; _	01/12/2015				
	3	ω	12	37	
	131				
	144				
_					
_					
_	Z	Z O	Z o	Z	
_					
	Ple Sel	Pie Sei	S _e .	ë ë	

	85095	85094	85093	85092	85091
	15/WS/0011	85094 14/LO/1291	85093 15/LO/0940	85092 14/SC/0171	85091 15/EM/0344
	122822	184513	179018	120104	183906
	HRA Approval	NHS Permission	NHS Permission	NHS Permission	NHS Permission
CCR3804 PLATFORM:	BALLAD: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma	PALLET - A phase I1 randomised study evaluating the biological and clinical effects of the combination of palocicilb with letrozole as neo adjuvant therapy in post-menopausal women with ER+primary breast cancer.	Victoria: GS-US- 312-0118 A phase 3 randomised open-label study evaluating the efficacy and safety of idelalisib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab for previously untreated chronic lymohocytic leukem	Add-Aspirin: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after therapy in common non-metastatic solid turnours.	randomised, double-blind, place-controlled study of the safety and efficacy of ametuximab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma
		16/09/2015	13/11/2015	10/07/2015	14/03/2016
		20/10/2015	22/12/2015	27/07/2015	23/03/2016
	N _o	Z _o	8	Yes	Yes
				15/12/2015 17	19/07/2016 9
		34	39		
				141	118
				158	127
	68				
	Zo	Z O	Z	Z	Z
	/04/2016 01				
	/04/2016 29/				
	01/04/2016 01/04/2016 29/04/2016 08/06/2016 08/06/2016 Sel				
	06/2016 08/				
	06/2016 Ple	Ple Sel·	Sel.	S B B	⊗ P e e e
)					

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=39&SubmissionId=4222&TrustId=1119

.					
85101 1	85100	85099	85098	85097	85096
85101 14/SC/0092 143836 NHS	85100 15/EM/0400 178129	85099 14/LO/0100	85098 15/LO/0691	85097 13/NW/0153 104669	85096 14/LO/1206
143836	178129	135429	174324	104669	154429
	NHS Permission	NHS Permission	NHS Permission	NHS Permission	NHS Permission
LASER: Laminator Airflow in Severe Asthma for Exacerbation Reduction. A multi-centre, randomised, double-blind, parallel group trial of the effectiveness of the noctural use of	SOPHIA - A Phase 3, Randomised Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 therapies and Require Systemic Treatment	APIPPRA - Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept	CHECKMATE 171: BMS-336558 A Safety Trial of Nivolumab (BMS- 936558) in Subjects With Advanced or Metastatic Non- Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen	CIPHER: Phase 11 multicentre study assessing the efficacy of Cabazitaxel in patients with HER2-negative metastatic breast cancer and having un-resectable brain metastases.	Planning treatment for oesophago- gastric cancer: a randomised maintenance trial.
30/06/2015	16/02/2016	02/11/2015	27/07/2015	16/02/2016	26/06/2015
07/07/2015	25/02/2016	04/11/2015	03/09/2015	23/02/2016	27/07/2015
Yes	No	Yes	Yes	ŏ	N ₀
21/08/2015 7	ω	31/12/2015 2	11/11/2015 38	7	0
				,	31
45		57	99		
52		59	107		
Yes	N _o	Yes	<u>N</u>	Z _o	N o
S Ple	S P e. e	Sel.	S P e	Ple Sel	Ple Sel

CTP Submission Platform - Submission (Version 1.0.3)

2/5/2018 85102 14/SC/1161 85103 12/WA/0374 98726 155743 NHS Permission NHS Permission e-ULTIMASTER
REGISTRY:
Prospective,
Single-arm,
Observational
Registry to further
Validate Safety
and Efficacy of the
Ultimaster DES in
unselected a tempreture controlled Laminator Airflow (LTA) Device (Airsonett) in adults HART Hughes
Abdominal Repair
Trial - Abdominal
wall claim
wall color
techniques to
reduce incidence
of incisional
hemias patients representing everyday clinical practice. 28/07/2015 18/02/2016 10/08/2015 23/02/2016 N_O No. G ವ Z 0 N_o

Sel-

Sel-

Showing records 1 to 25 of 32. Pages: 1 2 Next >

< Back

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by Exbos Limited the bespoke software specialists.

⊕exbos

http://ccfctp.nihr.ac.uk/Submission.aspx?MetaSubmissionId=39&SubmissionId=4222&TrustId=1119